mechanism
How endoplasmic reticulum stress and the unfolded protein response intersect with PKC signalling, and what published research suggests about tigilanol tiglate's convergence with these pathways.
mechanism
How the pro-apoptotic Bcl-2 family members Bax and Bak contribute to mitochondrial outer membrane permeabilization following EBC-46 exposure in tumour cell lines.
mechanism
How tigilanol tiglate (EBC-46) elevates intracellular reactive oxygen species, contributing to mitochondrial dysfunction and tumour cell death in preclinical work.
mechanism
Published mechanistic work links EBC-46 to NF-κB activation downstream of PKC. This article summarises how that pathway shapes the local inflammatory cascade after intratumoural injection.
mechanism
Experimental evidence on how tigilanol tiglate influences macrophage phenotype at the tumour site, shifting tumour-associated macrophages toward a pro-inflammatory M1 state.
mechanism
Among the compounds emerging from rainforest-derived pharmacognosy research, tigilanol tiglate (EBC-46) stands out for its unusually rapid and localised antitumour effect. Within hours of direct intratumoural injection, observable tumour destruction occurs — a timeline that differs markedly from conventional chemotherapy. Understanding why requires examining the compound's interaction with the
EBC-46
A deep-dive into how tigilanol tiglate (EBC-46) destroys tumours through three distinct pathways: PKC activation, rapid vascular disruption, and immune-mediated clearance — with full citations to the primary research.